Patiromer (Veltassa®) not recommended for use within NHS Scotland for treatment of hyperkalaemia in adults

This resubmission was not approved, as the submitting company did not present a sufficiently robust economic analysis to gain acceptance by the SMC. Contrastingly, NICE recommends patiromer for treating hyperkalaemia in a restricted group of adults.

Source:

Scottish Medicines Consortium

Resource links:

NICE Technology appraisal guidance [TA623]: Patiromer for treating hyperkalaemia